|
|
|
|
|
|
|
Request your FREE Special Report today and you'll |
Cardiovascular drug development company Cardiome Pharma Corp. (Nasdaq: CRME) this morning reported positive results for its phase 2 clinical trial of vernakalant (oral) when tested on the atrial fibrillation population. Shares surged 28.2%, or $1.76, to $8 in pre-market trading.
For detailed price information and recent news stories about Cardiome Pharma, click CRME.
Join Daily Profit today and get our unique perspective and investment ideas in your inbox every day.
Please tell us where we can send your free subscription. Plus, as a free gift, I'll rush you a copy of my Top 10 Forever Stocks - a special bonus report.
Wyatt Investment Research
c/o Business Financial Publishing
65 Railroad Street
PO Box 790
Richmond, VT 05477
